Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-04995274 for Emotional Processing in Depression
NCT03516604Phase 1Completed
- Sponsor
- University of Oxford
- Start
- May 2018
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of PF-04995274 in major depressive disorder (MDD), sponsored by University of Oxford. Primary endpoint: Hippocampal BOLD signal during fMRI. Started May 2018; status: completed.
02
Drugs
PF-04995274
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT03516604.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03516604.